Please assess the completion status of the following clinical trial:

Trial Title: Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female patients must have histologically or cytologically indicated breast cancer (stages I, II, III) eligible for adjuvant anthracycline chemotherapy \[FEC100 or AC-Taxol(paclitaxel) every 21 days.~* HER2 negative or HER2 positive breast cancer by immunohistochemistry (IHC3+) and/or fluorescent in-situ hybridization.~* Eastern cooperative oncology group (ECOG) performance status = 0, 1, 2~* Age ≥ 18 years old.~* Ability to understand and the willingness to sign a written informed consent document.~* The effects of L-carnitine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~Exclusion Criteria:~* Patients with evidence of metastatic breast cancer.~* Resting LV ejection fraction \< 50%.~* Patients having received previous anthracycline therapy or contraindication to anthracycline.~* Patients having a contraindication to L-carnitine therapy~* Dexrazoxane therapy at the time of enrollment.~* Patients with abnormal baseline bloodwork:~  * hemoglobin ≤ 100 mg/L~ * platelets ≤ 100 x 10\^9/L~ * white blood cells ≤ 4 x 10\^9/L~ * creatinine, AST, ALT, bilirubin \> 1.5 x the upper normal limits~* Participation in another randomized clinical trial.~* Patients having significant cardiac disease (previous myocardial infarction, congestive heart failure, or hemodynamically significant valvular heart disease) that would limit compliance with study requirements.~* Patients taking medication that may affect LV function (b-blockers, amiodarone, ACE-inhibitors, calcium channel blockers, or digoxin).~* Patients with symptoms of heart failure.~* Patients unable to participate in a study requiring long term follow up.~* Pregnant or lactating women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).